FDA Approves New Treatment for Pediatric Patients With Type 2 Diabetes

June 20, 2019

The FDA has approved the first non-insulin drug to treat type 2 diabetes in pediatric patients since 2000. Victoza (liraglutide) is an injection for treatment of pediatric patients 10 years or older with type 2 diabetes.

“The FDA encourages drugs to be made available to the widest number of patients possible when there is evidence of safety and efficacy,” said Lisa Yanoff, M.D, acting director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research. “Victoza has now been shown to improve blood sugar control in pediatric patients with type 2 diabetes. The expanded indication provides an additional treatment option at a time when an increasing number of children are being diagnosed with this disease.”

Read the FDA news release.